Full Press Release Details
Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Urology Care Devices & Platforms Market by Product Type (Diagnostics, Endoscopes, Imaging), Application (Benign Prostatic Hyperplasia, Kidney Cancer, Kidney Stone Management), End User, Procedure Type, Technology - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The urology care devices and platforms market is advancing rapidly as new clinical practices and patient-centered technologies drive transformation. Senior decision-makers now face complex choices shaped by evolving patient expectations, regulatory demands, and technology adoption priorities in delivering high-quality urological care.
Market Snapshot: Urology Care Devices & Platforms Market Outlook
The Urology Care Devices & Platforms Market grew from USD 47.74 billion in 2024 to USD 50.59 billion in 2025. It is expected to continue growing at a CAGR of 5.93%, reaching USD 67.46 billion by 2030. This sustained expansion reflects rising demand for advanced diagnostic and therapeutic solutions, increased prevalence of chronic urologic disorders, and broader adoption of digital health innovations. Technological breakthroughs and new care models are redefining the competitive landscape, compelling leaders to realign strategies across global regions and operational domains.
Scope & Segmentation: Navigating Critical Market Segments
Product Types: Diagnostics (biomarker assays, pH meters, urinary flow meters, urodynamic systems), Endoscopes (cystoscopes, nephroscopes, ureteroscopes), Imaging (CT scanning, MRI, ultrasound, X-ray), Lithotripsy (extracorporeal shockwave, laser, pneumatic, ultrasonic), Urinary Catheters (condom, Foley, intermittent, nephrostomy, ureteral), Urinary Stents (prostatic, ureteral, urethral).
Applications: Benign prostatic hyperplasia, kidney cancer (renal cell carcinoma, transition cell carcinoma, Wilms tumor), kidney stone management (calcium, cystine, struvite, uric acid stones), overactive bladder (idiopathic, neurogenic), prostate cancer (localized, metastatic, recurrent), urethral stricture (iatrogenic, idiopathic, traumatic), urinary incontinence (mixed, overflow, stress, urge), urinary tract infection (complicated, uncomplicated).
End Users: Ambulatory surgical centers, clinics, diagnostic centers, home care, hospitals.
Procedure Types: Invasive (catheterization, open surgery), minimally invasive (endoscopic, laparoscopic, percutaneous procedures), non-invasive (conservative management, external shockwave therapy, imaging).
Technologies: Electrohydraulic (high frequency, standard), laser (CO2, greenlight, holmium, thulium), magnetic resonance (MR spectroscopy, MRI-guided), optical (fluorescence, narrow band, white light imaging), pneumatic (ballistic, vibratory), RF (bipolar, monopolar), ultrasonic (high and low intensity).
Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and additional countries), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
Key Companies: Boston Scientific Corporation, Olympus Corporation, Medtronic plc, Coloplast A/S, Becton, Dickinson and Company, Teleflex Incorporated, ConvaTec Group plc, Intuitive Surgical, Inc., Stryker Corporation, Johnson & Johnson.
Key Takeaways: Strategic Insights for Decision-Makers
Pace of innovation is accelerating, with device design, data analytics, and integrated platforms enabling earlier diagnosis and minimally invasive interventions.
Collaboration across manufacturers, clinicians, and technology firms is central to building interoperable solutions, supporting seamless care transitions and improved patient experiences.
Minimally invasive and non-invasive therapies are gaining traction, reducing postoperative complications and enabling more patient-centric outpatient care settings.
Digital transformation is changing clinician workflows through AI-enhanced imaging, remote monitoring via sensors and mobile applications, and improved longitudinal care management.
Emergent market players and established manufacturers are diversifying portfolios by focusing on clinical sub-segments and geographic growth, notably in Asia-Pacific and Latin America.
Personalization of care, regulatory engagement, and evidence-based reimbursement strategies are becoming crucial to long-term market positioning and commercial success.
Tariff Impact: Responding to Evolving U.S. Trade Dynamics
New U.S. tariffs on imported urology devices in 2025 are reshaping supply chain strategies, elevating landed costs, and prompting organizations to reassess sourcing and manufacturing locations. Medical device manufacturers and providers are actively seeking alternative suppliers, revising procurement models, and exploring domestic and nearshoring options to sustain operational resilience. The regulatory environment is driving renewed attention to quality and efficiency, influencing pricing strategies and partnership opportunities.
Methodology & Data Sources
This market analysis is grounded in in-depth interviews with clinical leaders, procurement professionals, and industry executives. Primary insights are triangulated with secondary research from peer-reviewed journals, regulatory filings, and market reports. An expert validation process ensures alignment with current industry perspectives and the accuracy of technology trends.
Why This Report Matters
Empowers strategic planning by mapping technology evolution, stakeholder collaborations, and shifts in regional demand within urology care devices and platforms.
Delivers actionable insights for navigating regulatory, reimbursement, and procurement challenges in a dynamic market landscape.
Equips leadership with a robust foundation to identify growth opportunities, mitigate supply chain risks, and foster patient-centered innovation.
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2025-2030 |
| Estimated Market Value (USD) in 2025 | $50.59 Billion |
| Forecasted Market Value (USD) by 2030 | $67.46 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4.2. Market Sizing & Forecasting
5.1. Integration of AI-driven diagnostics for early detection of prostate cancer and kidney stones
5.2. Adoption of teleurology platforms to deliver remote urological consultations and patient monitoring
5.3. Development of minimally invasive robotic-assisted surgical systems tailored to complex urological procedures
5.4. Growth of wearable urinary incontinence monitoring devices offering real-time analytics for treatment optimization
5.5. Launch of advanced smart catheter solutions designed to reduce infections and enhance patient comfort
5.6. Expansion of point-of-care molecular testing platforms enabling rapid urinary tract infection diagnosis
5.7. Utilization of cloud-based patient management software for integrated urology care coordination and analytics
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Urology Care Devices & Platforms Market, by Product Type
8.2.1. Biomarker Assays
8.2.3. Urinary Flow Meters
8.2.4. Urodynamic Systems
8.3.3. Ureteroscopes
8.4.1. CT Scanning Systems
8.4.3. Ultrasound Systems
8.4.4. X Ray Systems
8.5.1. Extracorporeal Shockwave Lithotripsy
8.5.2. Laser Lithotripsy
8.5.3. Pneumatic Lithotripsy
8.5.4. Ultrasonic Lithotripsy
8.6. Urinary Catheters
8.6.1. Condom Catheters
8.6.2. Foley Catheters
8.6.3. Intermittent Catheters
8.6.4. Nephrostomy Catheters
8.6.5. Ureteral Catheters
8.7.1. Prostatic Stents
8.7.2. Ureteral Stents
8.7.3. Urethral Stents
9. Urology Care Devices & Platforms Market, by Application
9.2. Benign Prostatic Hyperplasia
9.3.1. Renal Cell Carcinoma
9.3.2. Transition Cell Carcinoma
9.4. Kidney Stone Management
9.4.1. Calcium Stones
9.4.2. Cystine Stones
9.4.3. Struvite Stones
9.4.4. Uric Acid Stones
9.5. Overactive Bladder
9.6. Prostate Cancer
9.7. Urethral Stricture
9.8. Urinary Incontinence
9.8.1. Mixed Incontinence
9.8.2. Overflow Incontinence
9.8.3. Stress Incontinence
9.8.4. Urge Incontinence
9.9. Urinary Tract Infection
9.9.2. Uncomplicated
10. Urology Care Devices & Platforms Market, by End User
10.2. Ambulatory Surgical Centers
10.4. Diagnostic Centers
11. Urology Care Devices & Platforms Market, by Procedure Type
11.2.1. Catheterization Interventions
11.2.2. Open Surgery
11.3. Minimally Invasive
11.3.1. Endoscopic Procedures
11.3.2. Laparoscopic Procedures
11.3.3. Percutaneous Procedures
11.4.1. Conservative Management